Nanjing Hicin Pharmaceutical Co., Ltd. Class A

Nanjing Hicin Pharmaceutical Co., Ltd. Class A

SSZSE:300584
28.30
CNY
-0.89
(-3.05%)
0.64EPS
52.23P/E
3.74BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.87
2.2
2.45
3.12
3.87
5.93
7.7
5.89
4.82
4.39
4.31
4.2
5.59
6.79
Basic EPS, GAAP
0.37
0.38
0.45
0.5
0.56
0.69
0.81
0.46
2.38
0.27
0.3
0.34
0.35
0.6
Free Cash Flow per Basic Share
0.04
-0.05
0.28
-0.09
-0.17
- -
0.45
-0.39
-0.29
-1.87
-1.44
-0.15
0.13
- -
Dividend per Share
0.01
0.02
0.08
0.07
0.21
0.2
0.25
0.31
0.18
0.3
0.05
0.12
0.16
0.16
Book Value per Share
1.84
2.22
2.61
3.07
4.31
4.84
5.45
5.66
7.92
7.92
8.23
8.52
8.78
9.09
Tangible Book Value per Share
1.72
1.94
2.34
2.8
4.08
4.52
4.93
4.46
6.48
6.49
6.83
7.26
7.76
8.19
Basic Weighted Avg Shares
91
90
90
90
118
120
120
120
120
120
120
120
120
120
Sales/Revenue/Turnover
170
198
221
281
455
712
925
706
578
526
518
504
671
815
Operating Margin (%)
22.32
21.21
21.47
19.63
17.36
14.11
13.27
10.16
5.9
8.5
10.38
11.89
13.37
18.7
Depreciation Expense
4
10
11
13
14
17
28
32
37
48
54
53
65
- -
Net Income, GAAP
33
34
40
45
66
83
97
55
286
32
36
40
42
72
Effective Tax Rate (%)
14.12
14
15
13.77
14.01
13.28
14.89
11.12
13.8
- -
3.64
2.11
13.89
26.89
Profit Margin (%)
19.64
17.31
18.25
16.11
14.42
11.69
10.52
7.82
49.43
6.16
7.01
7.97
6.27
8.79
Working Capital
22
17
30
26
210
123
138
113
1
61
-23
22
15
49
LT Debt
- -
- -
- -
- -
- -
44
- -
39
- -
- -
- -
72
54
57
Total Equity
166
200
235
276
518
581
654
679
948
951
987
1,038
1,100
1,091
Return on Invested Capital (%)
18.44
15.68
14.75
15.11
15.06
13.08
12.97
6.75
28.69
- -
3.14
3.12
2.89
5.79
Return on Capital (%)
19.8
16.77
16.3
16.09
15.32
13.76
13.86
7.64
29.67
- -
3.71
3.76
3.59
5.12
Return on Common Equity (%)
22.3
18.69
18.53
17.7
16.53
15.15
15.75
8.28
35.07
3.41
3.75
4
4.05
6.72

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
249
215
268
LT Borrowings
47
63
57
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
120
120
120
Market Capitalization
5,290
4,348
3,742

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
384
384
456
Cash, Cash Equivalents & STI
71
23
33
Accounts Receivable, Net
195
234
289
Inventories
86
90
89
Total Current Liabilities
360
324
407
Payables & Accruals
- -
- -
- -
ST Debt
249
215
268
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.84%
10.97%
5.94%
Free Cash Flow
987.46%
45.48%
-185.94%
Net Income, GAAP
41.39%
71.24%
4.58%
Sales/Revenue/Turnover
15.35%
0.34%
33.05%
Total Cash Common Dividend
41.81%
18.81%
40.82%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
105
132
124
144
504
2025
143
166
- -
200
671
2026
160
204
251
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.09
0.03
0.1
0.34
2025
0.13
0.12
- -
0.08
0.35
2026
0.14
0.12
0.25
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.07
0.02
0.02
0.12
2025
0.02
0.12
- -
0.02
0.16
2026
0.01
0.11
0.01
- -
- -

Company Description

CEO
Yu-Ping Cao
Full Time Employees
553
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No.1 Hengfa Road Nanjing JS China 210046
IPO Date
Jan 12, 2017
Website
hicin.cn
Business
Nanjing Hicin Pharmaceutical Co., Ltd. is a high-tech pharmaceutical enterprise specializing in the research, development, production, and marketing of pharmaceutical preparations, synthetic chemicals, and active pharmaceutical ingredients (APIs). The company manufactures a range of products including sterile lyophilized powders, cephalosporin lyophilized powders, solid dosage forms such as tablets, capsules, and granules, and synthetic APIs. Its main pharmaceutical product categories cover antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, cardiovascular and cerebrovascular medicines, immuno-modulatory agents, and diuretics. Key products include injectable landiolol hydrochloride, rivaroxaban tablets, tigecycline for injections, torasemide for injections, and cefazidone sodium for injections. Nanjing Hicin exports APIs such as omeprazole sodium for injection, cefepime hydrochloride for injection, and lansoprazole tablets to South Asian, South American, and European markets. The company was founded in 2003 and is headquartered in the Nanjing Economic and Technological Development Zone, Jiangsu Province, China. In recent years, Nanjing Hicin Pharmaceutical has expanded operations through the acquisition of Zhenjiang Dery Pharmaceutical Co., Ltd., which serves as a manufacturing base for APIs and intermediates. The company maintains advanced production facilities aligned with GMP standards and operates an R&D center located in Jiangsu Life Science and Technology Innovation Park, supporting continuous drug innovation with over 100 new drug certificates and more than 20 invention patents. Its strategic focus includes strengthening domestic and international cooperation to enhance innovation and market reach. The company is listed on the Shenzhen Stock Exchange (Ticker: 300584.SZ) since January 2017 and has received various national high-tech and innovation awards, reflecting its commitment to technological advancement and environmental protection standards. In 2025, Nanjing Hicin reported strong financial performance, indicating positive momentum in its growth trajectory and operational execution. The company actively pursues innovation in pharmaceutical R&D and production to meet evolving healthcare demands globally.